Table 2.
Cell surface marker phenotyping of immune cells between CS and controls.
| Parameters | Controls (n = 16) | Cushing syndrome
(n = 26) |
p value |
|---|---|---|---|
| Monocytes | |||
| CD14++CD16− classical (MN) | 42.2 ± 32.5 | 34.2 ± 30.1 | 0.082 |
| CD14++CD16−11b+ (%) | 80.8 ± 19.6 | 72.4 ± 32.4 | 0.227 |
| CD14++CD16+ intermediate (MN) | 28.7 ± 26.1 | 36.3 ± 25.1 | 0.047 ∗ |
| CD14++CD16+11b+ (%) | 48.1 ± 48.7 | 52.4 ± 44.8 | 0.432 |
| CD14+CD16++ nonclassical (MN) | 5.8 ± 3.8 | 7.1 ± 2.3 | 0.053 ∗ |
| CD14+CD16++11b+ (%) | 35.4 ± 41.1 | 38.4 ± 42.8 | 0.864 |
| Neutrophils | |||
| CD15+ (% N) | 47.1 ± 13.9 | 65.8 ± 24.6 | 0.027 ∗ |
| CD15+CD16+ (%) | 44.3 ± 12.7 | 66.6 ± 25.2 | 0.008 ∗ |
| CD15+CD16+11b (%) | 69.2 ± 29.1 | 80.6 ± 26.6 | 0.098 |
| CD16+11b (% N) | 94.2 ± 4.2 | 90.0 ± 22.7 | 0.460 |
| Lymphocytes | |||
| CD3+CD8+ (% L) | 26.8 ± 8.0 | 30.1 ± 11.9 | 0.435 |
| CD3+CD4+ (% L) | 54.2 ± 6.6 | 47.6 ± 18.6 | 0.207 |
| CD3+CD4+CD25+ (%) | 22.7 ± 11.1 | 20.7 ± 18.8 | 0.746 |
| NK (% L) | 18.4 ± 18.5 | 34.7 ± 32.2 | 0.019 ∗ |
| NKCD11b+ (%) | 37.5 ± 44.4 | 35.1 ± 36.0 | 0.889 |
Data are expressed as % ± standard deviation. MN: monocytes; N: neutrophils; L: lymphocytes. ∗p < 0.05.